Compare XPL & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | PLRX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 74.9M |
| IPO Year | 2000 | 2020 |
| Metric | XPL | PLRX |
|---|---|---|
| Price | $0.82 | $1.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $1.20 | ★ $2.67 |
| AVG Volume (30 Days) | 203.2K | ★ 422.0K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $1.09 |
| 52 Week High | $0.98 | $1.95 |
| Indicator | XPL | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.54 | 48.79 |
| Support Level | $0.68 | $1.13 |
| Resistance Level | $0.88 | $1.37 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 8.70 | 57.14 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.